Prostate Cancer
Rucaparib extends PFS in advanced prostate cancer
A randomized phase 3 trial that assessed rucaparib for certain men with advanced prostate cancer met its primary endpoint of improved PFS, according to topline data released by the agent’s manufacturer.
Genetic variants linked to aggressive prostate cancer in men of African ancestry
Researchers have identified genetic variants in prostate tumors of men of African descent that appear to be associated with African ancestry.
Long-course ADT plus radiotherapy provides survival benefit after prostatectomy
Long-course androgen depravation therapy extended metastasis-free survival compared with short-course ADT when added to radiotherapy after radical prostatectomy, results of the randomized phase 3 RADICALS-HD trial showed.
Single-port robotic system for prostatectomy ‘has made a huge difference,’ surgeon says
Smilow Cancer Hospital has introduced a new single-port robotic prostatectomy procedure that reduces the number of incisions and may minimize the risk for complications.
Top in hem/onc: Risk of alcohol-associated cancer; adverse events in prostate cancer
A Korean study published in JAMA Network Open found that individuals who increased their alcohol consumption were at higher risk for both alcohol-associated and all cancer types.
Genetic counseling relatively low cost, ‘should be offered to more at-risk patients’
Submitted medical claims and out-of-pocket costs for genetic counseling encounters appeared relatively low among patients with certain cancer types, according to a research letter published in JAMA Health Forum.
Common prostate cancer drugs may elevate risk for metabolic, cardiovascular adverse events
Both abiraterone and enzalutamide appeared to increase risk for metabolic and cardiovascular adverse events among older men with advanced prostate cancer who previously underwent androgen deprivation therapy, according to study results.
Metformin, testosterone therapies lower risk for certain hormone-related cancers in men
In a large cohort of men, pre‐diagnostic use of metformin and testosterone replacement therapy was associated with lower incidence of prostate and colorectal cancers, but not male breast cancer, according to research.
CV admission rates increase among patients with cancer
Rates for CV admissions among patients with cancer has increased, according to a study published in the European Heart Journal Quality of Care & Clinical Outcomes.Primary CV admissions are highest among patients with hematological cancer with the most common cause of admission being heart failure, according to the study.
FDA grants priority review to Lynparza regimen for advanced prostate cancer
The FDA granted priority review to olaparib as part of combination therapy treatment of metastatic castration-resistant prostate cancer.